Skip to content

Effects of Sulforaphane on Nurse Insomnia: The Mediating Role of Gut Microbiota

Effects of Sulforaphane on Nurse Insomnia: The Mediating Role of Gut Microbiota

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500107819
Enrollment
Unknown
Registered
2025-08-19
Start date
2025-06-19
Completion date
Unknown
Last updated
2025-08-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic insomnia disorder

Interventions

Non-insomnia group:NA
Intervention group:Sulforaphane
Control group:Starch tablets

Sponsors

Hunan Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Possession of a valid nursing license; 2. Currently engaged in full-time nursing work; 3. Insomnia group: Diagnosed with chronic insomnia according to ICSD-3 (Experiencing one or more of the following disturbances: difficulty falling asleep, difficulty staying asleep, early awakening. Difficulty falling asleep is defined as a sleep latency of >=30 minutes, and difficulty staying asleep is defined as waking up after falling asleep and staying awake for =30 minutes); 4. Non-insomnia group: Not diagnosed with chronic insomnia according to ICSD-3; 5. Currently engaged in night shift work and the duty will maintain during the study (averaging at least three night shifts per month, where a night shift involves working at least three hours between 0:00 and 6:00);

Exclusion criteria

Exclusion criteria: 1. Currently diagnosed with physical diseases, including tumors, cerebrovascular diseases, respiratory diseases, cardiovascular diseases, endocrine and metabolic disorders, other chronic inflammatory diseases, or bacterial, fungal, or viral infections in any part of the body; 2. Currently or previously diagnosed with mental illnesses, such as depression, anxiety disorders, schizophrenia, and bipolar disorder; 3. Breastfeeding, pregnant, or planning to become pregnant during the study period; 4. Allergic to the intervention reagents or placebo components used in the study; 5. Use of sleep-related medications within one month before recruitment; 6. Use of systematic antibiotics, antifungal medications within three months, or probiotic supplements within one month before recruitment; 7. Participating in any trial or dietary intervention program currently or within one month before recruitment;

Design outcomes

Primary

MeasureTime frame
The severity of insomnia;The diversity, composition and abundance of gut microbiota;

Secondary

MeasureTime frame
sleep quality;Non-targeted metabolomics analysis of faeces;Targeted detection of urinary creatinine;Targeted detection of urinary melatonin metabolite aMT6s;

Countries

China

Contacts

Public ContactYan Yu

Hunan Provincial People's Hospital

anniyu2015@163.com+86 135 7485 3513

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026